JP2024538719A5 - - Google Patents
Info
- Publication number
- JP2024538719A5 JP2024538719A5 JP2024521023A JP2024521023A JP2024538719A5 JP 2024538719 A5 JP2024538719 A5 JP 2024538719A5 JP 2024521023 A JP2024521023 A JP 2024521023A JP 2024521023 A JP2024521023 A JP 2024521023A JP 2024538719 A5 JP2024538719 A5 JP 2024538719A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252995P | 2021-10-06 | 2021-10-06 | |
| US63/252,995 | 2021-10-06 | ||
| PCT/US2022/045895 WO2023059795A1 (en) | 2021-10-06 | 2022-10-06 | Combination therapies using prmt5 inhibitors for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024538719A JP2024538719A (ja) | 2024-10-23 |
| JPWO2023059795A5 JPWO2023059795A5 (https=) | 2025-10-20 |
| JP2024538719A5 true JP2024538719A5 (https=) | 2025-10-20 |
Family
ID=84053165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024521023A Pending JP2024538719A (ja) | 2021-10-06 | 2022-10-06 | がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240398795A1 (https=) |
| EP (1) | EP4412607A1 (https=) |
| JP (1) | JP2024538719A (https=) |
| KR (1) | KR20240095421A (https=) |
| CN (1) | CN118251218A (https=) |
| AU (1) | AU2022360837A1 (https=) |
| CA (1) | CA3233157A1 (https=) |
| IL (1) | IL311663A (https=) |
| MX (1) | MX2024004171A (https=) |
| WO (1) | WO2023059795A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023202626A1 (zh) * | 2022-04-22 | 2023-10-26 | 北京望实智慧科技有限公司 | 稠和哒嗪酮化合物作为prmt5抑制剂 |
| CN119301101A (zh) * | 2022-07-29 | 2025-01-10 | 四川科伦博泰生物医药股份有限公司 | 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0922332D0 (en) * | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
| EP3177288A4 (en) * | 2014-08-04 | 2018-04-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3191592A1 (en) * | 2014-09-11 | 2017-07-19 | Novartis AG | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
| TW202122387A (zh) | 2019-09-12 | 2021-06-16 | 美商米瑞替療法公司 | Mta協同性之prmt5抑制劑 |
| AU2020410418A1 (en) * | 2019-12-18 | 2022-06-09 | Pfizer Inc. | Once daily cancer treatment regimen with a PRMT5 inhibitor |
| WO2021138578A1 (en) * | 2019-12-31 | 2021-07-08 | The Trustees Of Indiana University | Repurposing fda-approved drugs as a novel cancer therapeutic avenue through inhibition of prmt5 |
-
2022
- 2022-10-06 EP EP22800027.9A patent/EP4412607A1/en active Pending
- 2022-10-06 AU AU2022360837A patent/AU2022360837A1/en active Pending
- 2022-10-06 CA CA3233157A patent/CA3233157A1/en active Pending
- 2022-10-06 MX MX2024004171A patent/MX2024004171A/es unknown
- 2022-10-06 US US18/697,932 patent/US20240398795A1/en active Pending
- 2022-10-06 JP JP2024521023A patent/JP2024538719A/ja active Pending
- 2022-10-06 WO PCT/US2022/045895 patent/WO2023059795A1/en not_active Ceased
- 2022-10-06 KR KR1020247014554A patent/KR20240095421A/ko active Pending
- 2022-10-06 IL IL311663A patent/IL311663A/en unknown
- 2022-10-06 CN CN202280067397.9A patent/CN118251218A/zh active Pending